{ "schemaVersion": "2.1", "datasetVersion": "2026-09-11.1", "generatedAt": "2026-09-11", "reviewStatus": "Editorial source review is complete. This edition has not been independently medically reviewed.", "editorialBoundary": "Source-checked educational summaries. Topics require evidence and editorial review. This dataset is not a personal treatment plan.", "citation": "When you cite a record, include The Peptide Field, its canonicalPath, this dataset version, and every source used for the claim.", "reuse": "This endpoint grants no additional reuse license. Keep the verdict, scope, evidence basis, review date, and source links together. Do not present a record as medical advice or medical review.", "changeLogPath": "/corrections#correction-ledger", "contactPath": "/corrections", "dataset": "peptide-evidence-checker-record", "canonicalPath": "/peptides/ipamorelin", "canonicalUrl": "https://thepeptidefield.com/peptides/ipamorelin", "record": { "slug": "ipamorelin", "name": "Ipamorelin", "className": "Ghrelin-receptor agonist · GH secretagogue", "sequenceLabel": "Synthetic pentapeptide · investigational", "tier": "Emerging", "statusLine": "Still being studied; no FDA-approved product identified", "profile": { "humanOutcomes": { "level": "Limited", "note": "A phase 2 trial did not show significant benefit on its key efficacy endpoint." }, "humanPharmacology": { "level": "Moderate", "note": "Dose-escalation work characterizes short-lived GH release in healthy volunteers." }, "safetyKnowledge": { "level": "Limited", "note": "Route-specific data are sparse and FDA identifies serious safety concerns." }, "productCertainty": { "level": "Unclear", "note": "No approved formulation anchors identity, purity, or equivalence in the consumer market." } }, "oneLine": "A short human study measured growth-hormone release, but it did not prove health benefits. A different phase 2 study did not show benefit on its main or other measured outcomes.", "reviewedAt": "July 23, 2026", "whatItIs": "Ipamorelin can trigger the body to release growth hormone. Ipamorelin is a synthetic peptide that activates the ghrelin receptor and stimulates growth-hormone release. Human pharmacology studies and a clinical efficacy trial exist, making it a useful example of why biological activity and clinical benefit must be graded separately.", "whatWeKnow": "The short hormone-response study was in healthy male volunteers. The phase 2 study was after bowel surgery. A dose-escalation study in healthy male volunteers characterized ipamorelin exposure and a short episode of GH release. In a multicenter, double-blind, placebo-controlled phase 2 trial after bowel surgery, the drug was described as well tolerated in that setting but did not significantly improve the key or secondary efficacy outcomes.", "whatWeDoNotKnow": "Those studies do not establish popular claims about muscle gain, fat loss, recovery, anti-aging, or sleep. They also do not establish the safety or quality of consumer products, compounded combinations, or different routes.", "safetyBoundary": "FDA identifies immunogenicity, aggregation, impurity, and characterization concerns. The agency also cites serious adverse events, including death, in intravenous gastric-motility research and says it lacks sufficient information for other promoted injectable routes.", "claims": [ { "claim": "“Ipamorelin stimulates GH release in people.”", "verdict": "Supported with scope", "explanation": "A human dose-escalation study measured an episode of GH release. That is a pharmacodynamic effect.", "category": "Mechanism and biomarkers", "evidenceBasis": "Human pharmacology", "scope": "Short-term GH pharmacodynamics in the healthy volunteers and route studied.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/10496658/" ] }, { "claim": "“A GH response proves better recovery or body composition.”", "verdict": "Not established", "explanation": "A biomarker response is not a clinical outcome, and the identified studies did not establish those benefits.", "category": "Performance and recovery", "evidenceBasis": "No reliable human outcome evidence", "scope": "Recovery and body-composition outcomes not established by GH pharmacology or the postoperative-ileus trial.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/10496658/", "https://pubmed.ncbi.nlm.nih.gov/25331030/" ] }, { "claim": "“Ipamorelin worked in its phase 2 surgical trial.”", "verdict": "Misleading", "explanation": "The randomized trial reported no significant difference from placebo on its key and secondary efficacy analyses.", "category": "Clinical outcomes", "evidenceBasis": "Randomized human outcomes", "scope": "The postoperative-ileus population, intervention, and efficacy endpoints in the phase 2 trial.", "sourceUrls": [ "https://pubmed.ncbi.nlm.nih.gov/25331030/" ] } ], "sources": [ { "label": "Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers", "publisher": "PubMed · Pharmaceutical Research", "url": "https://pubmed.ncbi.nlm.nih.gov/10496658/", "kind": "Human pharmacology", "year": 1999, "accessedAt": "2026-07-23" }, { "label": "Randomized proof-of-concept study of ipamorelin for postoperative ileus", "publisher": "PubMed · International Journal of Colorectal Disease", "url": "https://pubmed.ncbi.nlm.nih.gov/25331030/", "kind": "Randomized trial", "year": 2015, "accessedAt": "2026-07-23" }, { "label": "Certain bulk drug substances that may present significant safety risks", "publisher": "U.S. Food and Drug Administration", "url": "https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks", "kind": "Regulatory", "year": 2026, "accessedAt": "2026-07-23" }, { "label": "2026 prohibited list", "publisher": "World Anti-Doping Agency", "url": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list", "kind": "Anti-doping", "year": 2026, "accessedAt": "2026-07-23" } ], "aliases": [ "ipamorelin acetate", "NNC 26-0161", "growth hormone secretagogue" ], "family": "Growth signaling", "evidenceContext": "Investigational human outcomes", "productContext": "Human studies used defined study material and routes. They do not establish the identity, safety, or equivalence of compounded mixtures or consumer-market products.", "approvedProducts": [], "productRecords": [], "indications": [ "No FDA-approved indication" ], "reviewedAtISO": "2026-07-23", "reviewHistory": [ { "date": "2026-07-23", "note": "Expanded trial-outcome, route, and product-quality boundaries." } ], "antiDoping": "Growth-hormone secretagogues and mimetics are prohibited under the current WADA framework.", "antiDopingReview": { "status": "Prohibited", "detail": "Growth-hormone secretagogues and mimetics are prohibited under the current WADA framework.", "sourceUrl": "https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list", "reviewedAtISO": "2026-07-23" }, "relatedSlugs": [ "cjc-1295", "tesamorelin", "sermorelin" ] } }